查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1807515

感染疾病體外診斷市場（按產品、技術、病原體、應用和最終用戶分類）—2025-2030 年全球預測

Infectious Diseases In-Vitro Diagnostics Market by Product, Technology, Pathogen, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年感染疾病體外診斷市值將達251.3億美元，2025年將達266.2億美元，複合年成長率為6.14%，到2030年將達359.5億美元。

主要市場統計數據
基準年2024年 251.3億美元
預計2025年 266.2億美元
預計2030年 359.5億美元
複合年成長率（%） 6.14%

在快速病原體鑑定可能決定疫情是否已控制的環境下，感染疾病的體外診斷已成為公共衛生基礎設施的關鍵。實驗室決策者越來越依賴先進的儀器和整合服務解決方案來提供及時、準確且經濟高效的結果。在新分子技術、自動化數位資料管理整合的推動下，該領域正在經歷重大變革，從基礎的微生物培養基發展到先進的次世代定序平台。

此外，公共衛生機構和醫療保健提供者要求在不犧牲靈敏度或特異性的情況下提高通量。這推動了試劑化學、檢測方法設計和儀器人體工學的持續創新。同時，世界各地的監管機構正在完善核准途徑，優先考慮診斷準確性和病人安全，這進一步凸顯了對穩健品管系統的需求。因此，產業相關人員必須在複雜的競爭格局中探索，同時利用新興技術的潛力來保持競爭力，並滿足全球對快速感染疾病監測和應對的需求。

一個關鍵的技術、監管和市場採用的轉折點，將重新定義全球感染疾病體外診斷策略

隨著新技術的普及和法律規範的演變，感染疾病體外診斷領域正在經歷模式轉移。等溫擴增和高通量定序的進步使得病原體檢測更快、更全面，而數免疫檢測平台則整合了人工智慧，以增強結果解讀。因此，分散式檢查模式正在興起，使診斷能力更貼近照護現場，並且能夠制定更早的干涉策略。

2025 年美國關稅對感染疾病體外診斷產業供應鏈、成本與競爭動態的影響

美國將於2025年生效的新關稅將對進口診斷設備和耗材造成巨大的成本壓力。實驗室和診斷公司正努力應對自動化培養系統、免疫檢測分析儀和分子檢測試劑採購成本的上升。因此，許多公司正在重新評估其供應商組合和籌資策略，以減輕供應鏈中斷的影響並維持財務韌性。

來自主要市場細分的洞察揭示了感染疾病體外診斷的產品、技術、病原體、應用和最終用戶動態

感染疾病診斷產品包括檢測儀器、試劑、試劑套件、軟體和服務，每一項都在實驗室工作流程中發揮至關重要的作用。儀器種類繁多，從自動化微生物培養系統到用於高通量檢測的先進免疫檢測和PCR分析儀。試劑和套件包括免疫檢測檢測套組、針對各種病原體最佳化的微生物培養基，以及專為精確分子擴增設計的高靈敏度PCR試劑。在服務方面，諮詢專業知識可指導實驗室完成驗證流程，資料管理平台可確保安全且有效率地處理大型資料集，維護支援服務可維護儀器效能並最大限度地減少停機時間。

區域分析重點介紹美洲、歐洲、中東和非洲以及亞太地區感染疾病體外診斷領域的機會和挑戰

美洲地區在尖端診斷平台的採用方面繼續保持領先地位，這得益於其強大的醫療基礎設施和充足的公共衛生資金。受大規模篩檢計畫和持續監測活動需求的推動，該地區正在快速普及自動化免疫檢測系統和分子檢測解決方案。同時，關稅變化和供應鏈重組正促使企業加強在北美和南美的本地夥伴關係和製造能力。

對感染疾病體外診斷產業成長的關鍵參與者的創新、合作夥伴關係和擴張計劃進行策略性評估

感染疾病診斷領域的領先公司正透過在檢測開發、自動化和數位化整合方面的持續創新來推動成長。與儀器製造商和試劑開發商建立策略聯盟，正在打造捆綁解決方案，從而簡化採購流程並縮短檢驗時間。同時，收購和合資企業使老牌跨國公司能夠拓展其地域市場並獲得利基技術，而新興的專業公司則正在快速分子檢測和人工智慧增強免疫檢測等高成長領域站穩腳跟。

確定感染疾病體外診斷市場的新興趨勢，並向行業領導者提供可行的建議，以最佳化營運並獲得競爭優勢。

為了保持競爭力，產業領導者應優先考慮模組化平台架構，以實現快速部署偵測和無縫擴展。投資靈活的製造流程並建立多層次的供應商網路，可以幫助企業提高供應鏈的彈性，並減輕未來貿易政策變化的影響。與合約開發和製造合作夥伴的策略合作可以進一步加快產品上市速度，同時降低資本支出。

採用嚴謹的調查方法，利用資料收集、分析方法和檢驗流程來支持感染疾病診斷市場研究

本研究綜合了大量二手資料的研究結果，包括同行評審期刊、監管出版物和企業資料披露文件。為了檢驗訪談。定量資料點與案例研究和試點實施中的真實世界證據進行了三角檢驗，以確保準確性和有效性。

結論重點強調了感染疾病體外診斷相關人員的關鍵發現、市場影響和策略考慮

總而言之，感染疾病體外診斷市場正處於關鍵的十字路口，受技術突破、監管格局變化和貿易政策演變的驅動。隨著實驗室和製造商適應新的關稅環境，採購和生產的策略調整可能會變得越來越重要。細分市場洞察凸顯了建構涵蓋儀器、試劑和數位服務的多元化產品組合的必要性，以滿足不同終端用戶的需求。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 開發可攜式等溫擴增系統以支援感染疾病爆發期間的現場部署
  • 採用基於 CRISPR 的診斷技術將徹底改變高特異性的即時病原體檢測
  • 分散式近患者檢測解決方案的興起，實現了快速的床邊抗菌素抗藥性分析
  • 擴展的數免疫檢測平台提高了敗血症早期生物標記識別的靈敏度
  • 多重 PCR 檢測的整合加速了臨床環境中新發呼吸道病毒的同時檢測
  • 自動化微生物學工作流程中人工智慧驅動的模式識別的出現提高了吞吐量
  • 微流體實驗室晶片設備的發展促進了偏遠地區媒介傳播疾病的現場檢測
  • 擴大使用次世代定序進行醫院感染控制中的全面病原體監測
  • 報銷政策的變化推動了大型醫療網路採用高通量血液培養診斷
  • 診斷公司和製藥公司合作推動針對性抗病毒治療的伴隨體外診斷檢測

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章：2025年美國關稅的累積影響

第8章感染疾病體外診斷市場（依產品）

  • 裝置
    • 自動化培養系統
    • 免疫檢測設備
    • PCR設備
  • 試劑和套件
    • 免疫檢測套件
    • 微生物培養基
    • PCR試劑
  • 軟體和服務
    • 諮詢服務
    • 資料管理軟體
    • 維護和支援服務

第9章感染疾病體外診斷市場（依技術）

  • 免疫檢測
    • 化學冷光免疫檢測
    • 酵素結合免疫吸附試驗
    • 螢光免疫分析法
    • 橫向流動化驗
  • 微生物培養
  • 分子診斷
    • 等溫擴增
    • 次世代定序
    • 聚合酵素鏈鎖反應

第 10 章感染疾病體外診斷市場（依病原體）

  • 細菌
    • 腸桿菌科
    • 結核分枝桿菌
    • 金黃色葡萄球菌
  • 真菌
  • 寄生蟲
  • 病毒性的
    • 肝炎病毒
    • 人類免疫力缺乏病毒
    • 流感病毒

第11章感染疾病體外診斷市場（依應用）

  • 診斷
  • 流行病學監測
  • 監控
  • 篩檢

第 12 章感染疾病體外診斷市場（依最終用戶）

  • 學術研究機構
  • 診所
  • 醫院
  • 實驗室

13.美洲感染疾病體外診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲感染疾病體外診斷市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15.亞太感染疾病體外診斷市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • FPNV定位矩陣2024
  • 競爭分析
    • Abbott Laboratories
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Danaher Corporation
    • DiaSorin SpA
    • Epitope Diagnostics, Inc.
    • F. Hoffmann La-Roche Ltd.
    • Grifols, SA
    • Hologic, Inc.
    • Illumina, Inc.
    • InBios International, Inc.
    • Koninklijke Philips NV
    • Merck KGaA
    • Meril Life Sciences Pvt. Ltd.
    • OraSure Technologies, Inc.
    • Qiagen NV
    • Quest Diagnostics
    • Quidel Corporation
    • Siemens Healthineers AG
    • Sysmex Corporation
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech PLC
    • Vela Diagnostics

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-A339DAEFAD44

The Infectious Diseases In-Vitro Diagnostics Market was valued at USD 25.13 billion in 2024 and is projected to grow to USD 26.62 billion in 2025, with a CAGR of 6.14%, reaching USD 35.95 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 25.13 billion
Estimated Year [2025] USD 26.62 billion
Forecast Year [2030] USD 35.95 billion
CAGR (%) 6.14%

In an environment where rapid pathogen identification can mean the difference between containment and outbreak, in-vitro diagnostics for infectious diseases have become pivotal to public health infrastructure. Laboratory decision-makers are increasingly reliant on advanced instruments and integrated service solutions to deliver timely, accurate, and cost-effective results. Driven by the convergence of novel molecular techniques, automation, and digital data management, the sector is experiencing a profound transformation that extends from basic microbial culture media to sophisticated next-generation sequencing platforms.

Furthermore, public health agencies and healthcare providers are demanding improved throughput without sacrificing sensitivity or specificity. This has spurred continuous innovation in reagent chemistry, assay design, and instrumentation ergonomics. At the same time, regulatory agencies around the world are refining approval pathways, prioritizing diagnostic accuracy and patient safety, which reinforces the need for robust quality management systems. As a result, industry stakeholders must navigate complex compliance landscapes while harnessing the potential of emerging technologies to stay competitive and address global needs for rapid infectious disease surveillance and response.

Critical Transformative Shifts in Technology, Regulation, and Market Adoption Redefining Infectious Diseases In-Vitro Diagnostic Strategies Worldwide

The landscape of infectious diseases in-vitro diagnostics is undergoing a paradigm shift as novel technologies gain traction and regulatory frameworks evolve. Advances in isothermal amplification and high-throughput sequencing are enabling faster, more comprehensive pathogen detection, while digital immunoassay platforms are integrating artificial intelligence to enhance result interpretation. As a result, decentralized testing models are emerging, bringing diagnostic capabilities closer to point-of-care settings and enabling earlier intervention strategies.

Simultaneously, regulatory bodies are harmonizing global approval processes, which facilitates more streamlined market access but also raises the bar for clinical validation and post-market surveillance. This alignment encourages international collaboration, accelerates technology transfer, and drives investment into standardized manufacturing practices. Consequently, stakeholders must recalibrate their development roadmaps and supply chain strategies to accommodate both heightened regulatory scrutiny and the growing demand for rapid, multiplexed diagnostic solutions.

Comprehensive Analysis of the 2025 United States Tariff Effects on Supply Chains, Costs, and Competitive Dynamics within the Infectious Diseases IVD Industry

The implementation of new United States tariff measures in 2025 has introduced significant cost pressures on imported diagnostic instruments and consumables. Laboratories and diagnostic companies are grappling with increased procurement expenses for automated culture systems, immunoassay analyzers, and molecular assay reagents. Consequently, many organizations are reevaluating their vendor portfolios and sourcing strategies to mitigate supply chain disruptions and maintain financial resilience.

In response, several manufacturers have accelerated domestic production initiatives and formed strategic alliances with local suppliers to reduce import dependency. This realignment of supply networks is reshaping the competitive landscape, with vertically integrated firms gaining an advantage through in-house reagent and instrument production. Over the long term, the tariff impact may lead to increased pricing transparency and a shift towards more localized manufacturing footprints, enabling faster response times to emerging public health threats.

Insights from Key Market Segmentation Revealing Distinct Product, Technology, Pathogen, Application, and End User Dynamics in Infectious Diseases IVD

The product spectrum in infectious diseases diagnostics encompasses instruments, reagents and kits, as well as software and services, each playing a vital role in laboratory workflows. Instruments range from automated microbial culture systems to advanced immunoassay and PCR analyzers tailored for high-throughput testing. Reagent and kit offerings include immunoassay test kits, microbial culture media optimized for a variety of pathogens, and highly sensitive PCR reagents designed for precise molecular amplification. On the services side, consulting expertise guides laboratory validation processes, data management platforms ensure secure and efficient handling of large datasets, and maintenance support services uphold instrument performance and minimize downtime.

Technology segmentation reveals the predominance of immunoassays for rapid antigen and antibody detection, microbiology culture techniques for traditional pathogen isolation, and molecular diagnostics for comprehensive genomic analysis. Within immunoassays, modalities such as chemiluminescence, enzyme-linked immunosorbent assays, fluorescence immunoassays, and lateral flow formats each offer distinct operational advantages. Molecular diagnostics extend from isothermal amplification methods to next-generation sequencing and polymerase chain reaction workflows, supporting everything from point-of-care screening to extensive epidemiological studies.

Pathogen-focused insights demonstrate that bacterial testing demand, driven by Enterobacteriaceae, Mycobacterium tuberculosis, and Staphylococcus aureus assays, remains strong alongside viral diagnostics targeting hepatitis, HIV, and influenza viruses. Application-based analysis underscores critical use cases in diagnosis, epidemiological surveillance, ongoing monitoring of treatment efficacy, and large-scale screening initiatives. End-user segmentation highlights that academic research institutions spearhead innovation, clinics and hospitals deliver patient-centric testing, and specialized laboratories provide high-complexity services, collectively forming an ecosystem that responds to evolving infectious disease challenges.

Regional Analysis Unveiling Opportunities and Challenges across Americas, Europe Middle East Africa, and Asia Pacific in Infectious Diseases Diagnostics

The Americas continue to lead in the adoption of cutting-edge diagnostic platforms, supported by robust healthcare infrastructure and extensive funding for public health initiatives. This region exhibits rapid uptake of automated immunoassay systems and molecular testing solutions, driven by the need for large-scale screening programs and ongoing surveillance efforts. At the same time, supply chain recalibrations following tariff changes have prompted companies to strengthen local partnerships and manufacturing capabilities within North and South America.

In Europe, the Middle East, and Africa, regulatory harmonization under the European In-Vitro Diagnostic Regulation is creating a unified framework for product approval, enhancing market predictability. Nonetheless, funding constraints in certain emerging markets and logistical hurdles in remote areas are shaping differential adoption rates. Meanwhile, Asia-Pacific is experiencing remarkable growth due to government-led screening campaigns, expanding laboratory networks in urban centers, and a growing emphasis on cost-effective assay solutions. Local manufacturing ecosystems are evolving rapidly, enabling faster product launches and fostering competitive pricing strategies to meet diverse regional needs.

Strategic Evaluation of Leading Players' Innovation, Partnership, and Expansion Initiatives Driving Growth in the Infectious Diseases In-Vitro Diagnostic Sector

Leading players in the infectious diseases diagnostics space are driving growth through continuous innovation in assay development, automation, and digital integration. Strategic collaborations between instrument manufacturers and reagent developers are forging bundled solutions that simplify procurement and reduce validation timelines. At the same time, acquisitions and joint ventures are enabling established multinationals to expand their geographic footprint and access niche technologies, while emerging specialized firms are carving out positions in high-growth segments such as rapid molecular assays and AI-enhanced immunoassays.

Furthermore, companies are investing in digital health platforms that aggregate testing data to deliver real-time insights into outbreak trends, antimicrobial resistance patterns, and patient outcomes. These initiatives not only enhance end-user engagement but also foster recurring revenue streams through software subscriptions and service contracts. As the competitive landscape intensifies, differentiation will hinge on the ability to offer comprehensive solutions that seamlessly integrate instruments, consumables, and data analytics into a unified diagnostic ecosystem.

Actionable Recommendations for Industry Leaders to Navigate Emerging Trends, Optimize Operations, and Enhance Competitiveness in Infectious Disease IVD Market

To maintain a competitive edge, industry leaders should prioritize modular platform architectures that enable rapid assay deployment and seamless scalability. By investing in flexible manufacturing processes and establishing multi-tiered supplier networks, organizations can enhance supply chain resilience and mitigate the impact of future trade policy shifts. Strategic collaboration with contract development and manufacturing partners can further accelerate time to market while reducing capital outlay.

In parallel, integrating data management and analytics into diagnostic offerings will empower laboratories to derive actionable insights and improve operational efficiency. Companies that foster open interoperability standards and invest in cybersecurity measures will build trust and drive adoption of digital solutions. Moreover, engaging proactively with regulatory bodies to shape evolving frameworks can streamline approval processes and provide early visibility into compliance requirements.

Finally, expanding into underserved geographies through public-private partnerships and capacity-building initiatives will unlock new growth opportunities. By tailoring product portfolios to local clinical needs and price sensitivities, organizations can strengthen their market presence and contribute to global health security initiatives.

Rigorous Research Methodology Leveraging Data Collection, Analysis Techniques, and Validation Processes Underpinning the Infectious Diseases Diagnostics Market Study

This study synthesizes insights from extensive secondary research, including examination of peer-reviewed journals, regulatory publications, and corporate disclosures. To validate findings, structured interviews were conducted with senior executives, laboratory directors, and key opinion leaders across diagnostics, public health, and research institutions. Quantitative data points were triangulated with real-world evidence from case studies and pilot implementations to ensure accuracy and relevance.

Analytical techniques encompassed comparative benchmarking of assay performance, scenario analysis to assess tariff impact under various trade regimes, and qualitative assessment of emerging technology pipelines. A multi-stage validation process was employed, encompassing internal peer review, expert advisory board feedback, and cross-referencing with regional regulatory updates. This rigorous approach ensures that the conclusions and recommendations reflect both current market realities and anticipated industry trajectories.

Conclusive Insights Highlighting Key Findings, Market Implications, and Strategic Considerations for Stakeholders in Infectious Disease In-Vitro Diagnostics

In conclusion, the infectious diseases in-vitro diagnostics sector is poised at a critical juncture, driven by technological breakthroughs, shifting regulatory landscapes, and evolving trade policies. As laboratories and manufacturers adapt to new tariff environments, strategic realignments in sourcing and production will become increasingly important. The segmentation insights underscore the necessity for diversified portfolios, spanning instruments, reagents, and digital services, to meet heterogeneous end-user demands.

Regional dynamics reveal that while established markets will continue to benefit from advanced diagnostic infrastructures, high-growth potential lies in emerging economies that are scaling up screening and surveillance capabilities. Ultimately, success in this market will depend on the ability to integrate innovative assay platforms with robust data analytics, maintain compliance amidst tightening regulations, and pursue agile partnerships that drive value across the diagnostic continuum.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Development of portable isothermal amplification systems supporting field deployment during epidemic outbreaks
  • 5.2. Adoption of CRISPR-based diagnostics revolutionizing point-of-care pathogen detection with high specificity
  • 5.3. Rise of decentralized near-patient testing solutions enabling rapid antimicrobial resistance profiling at the bedside
  • 5.4. Expansion of digital immunoassay platforms improving sensitivity in early sepsis biomarker identification
  • 5.5. Integration of multiplexed PCR assays accelerating simultaneous detection of emerging respiratory viruses in clinical settings
  • 5.6. Emergence of artificial intelligence-driven pattern recognition in automated microbiology workflows enhancing throughput
  • 5.7. Growth of microfluidic lab-on-a-chip devices facilitating on-site detection of vector-borne diseases in remote regions
  • 5.8. Increasing use of next-generation sequencing for comprehensive pathogen surveillance in hospital infection control
  • 5.9. Shifting reimbursement policies boosting adoption of high-throughput blood culture diagnostics in large healthcare networks
  • 5.10. Collaboration between diagnostics and pharmaceutical companies driving companion IVD tests for targeted antiviral therapies

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Infectious Diseases In-Vitro Diagnostics Market, by Product

  • 8.1. Introduction
  • 8.2. Instruments
    • 8.2.1. Automated Culture Systems
    • 8.2.2. Immunoassay Instruments
    • 8.2.3. PCR Instruments
  • 8.3. Reagents & Kits
    • 8.3.1. Immunoassay Kits
    • 8.3.2. Microbial Culture Media
    • 8.3.3. PCR Reagents
  • 8.4. Software & Services
    • 8.4.1. Consulting Services
    • 8.4.2. Data Management Software
    • 8.4.3. Maintenance & Support Services

9. Infectious Diseases In-Vitro Diagnostics Market, by Technology

  • 9.1. Introduction
  • 9.2. Immunoassays
    • 9.2.1. Chemiluminescence Immunoassay
    • 9.2.2. Enzyme Linked Immunosorbent Assay
    • 9.2.3. Fluorescence Immunoassay
    • 9.2.4. Lateral Flow Assay
  • 9.3. Microbiology Culture
  • 9.4. Molecular Diagnostics
    • 9.4.1. Isothermal Amplification
    • 9.4.2. Next Generation Sequencing
    • 9.4.3. Polymerase Chain Reaction

10. Infectious Diseases In-Vitro Diagnostics Market, by Pathogen

  • 10.1. Introduction
  • 10.2. Bacterial
    • 10.2.1. Enterobacteriaceae
    • 10.2.2. Mycobacterium Tuberculosis
    • 10.2.3. Staphylococcus Aureus
  • 10.3. Fungal
  • 10.4. Parasitic
  • 10.5. Viral
    • 10.5.1. Hepatitis Virus
    • 10.5.2. Human Immunodeficiency Virus
    • 10.5.3. Influenza Virus

11. Infectious Diseases In-Vitro Diagnostics Market, by Application

  • 11.1. Introduction
  • 11.2. Diagnosis
  • 11.3. Epidemiological Surveillance
  • 11.4. Monitoring
  • 11.5. Screening

12. Infectious Diseases In-Vitro Diagnostics Market, by End User

  • 12.1. Introduction
  • 12.2. Academic Research Institution
  • 12.3. Clinic
  • 12.4. Hospital
  • 12.5. Laboratory

13. Americas Infectious Diseases In-Vitro Diagnostics Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Infectious Diseases In-Vitro Diagnostics Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Infectious Diseases In-Vitro Diagnostics Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. Becton, Dickinson and Company
    • 16.3.3. Bio-Rad Laboratories, Inc.
    • 16.3.4. bioMerieux SA
    • 16.3.5. Danaher Corporation
    • 16.3.6. DiaSorin S.p.A
    • 16.3.7. Epitope Diagnostics, Inc.
    • 16.3.8. F. Hoffmann La-Roche Ltd.
    • 16.3.9. Grifols, S.A.
    • 16.3.10. Hologic, Inc.
    • 16.3.11. Illumina, Inc.
    • 16.3.12. InBios International, Inc.
    • 16.3.13. Koninklijke Philips N.V.
    • 16.3.14. Merck KGaA
    • 16.3.15. Meril Life Sciences Pvt. Ltd.
    • 16.3.16. OraSure Technologies, Inc.
    • 16.3.17. Qiagen N.V.
    • 16.3.18. Quest Diagnostics
    • 16.3.19. Quidel Corporation
    • 16.3.20. Siemens Healthineers AG
    • 16.3.21. Sysmex Corporation
    • 16.3.22. Thermo Fisher Scientific Inc.
    • 16.3.23. Trinity Biotech PLC
    • 16.3.24. Vela Diagnostics

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET: RESEARCHAI
  • FIGURE 26. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 27. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET: RESEARCHCONTACTS
  • FIGURE 28. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY AUTOMATED CULTURE SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIAL CULTURE MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIAL CULTURE MEDIA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PCR REAGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MAINTENANCE & SUPPORT SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY CULTURE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ENTEROBACTERIACEAE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MYCOBACTERIUM TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MYCOBACTERIUM TUBERCULOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STAPHYLOCOCCUS AUREUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY FUNGAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PARASITIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HEPATITIS VIRUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY EPIDEMIOLOGICAL SURVEILLANCE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY LABORATORY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 121. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 123. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 125. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 127. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 129. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 143. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 144. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 145. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 146. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 147. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 149. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 150. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 151. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 152. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 153. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 154. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 155. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 156. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 157. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 158. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 159. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 161. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 164. UNITED STATES INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 165. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 166. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 167. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 168. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 169. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 170. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 171. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 172. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 173. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 174. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 175. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 176. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 177. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 178. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 179. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 180. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 181. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 182. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 183. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 184. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 185. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 187. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. CANADA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 189. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 190. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 191. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 192. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 193. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 194. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 195. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 196. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 197. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 199. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 200. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 201. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 203. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 205. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 207. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 208. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 209. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. MEXICO INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 213. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 214. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 215. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 216. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 217. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 218. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 219. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 220. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 221. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 223. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 224. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 225. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 226. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 227. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 228. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 229. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 230. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 231. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 232. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 233. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 235. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. BRAZIL INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 237. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 238. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 239. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 240. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 241. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 242. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 243. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 244. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 245. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 248. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 249. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 250. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 251. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 252. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2025-2030 (USD MILLION)
  • TABLE 253. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2018-2024 (USD MILLION)
  • TABLE 254. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY BACTERIAL, 2025-2030 (USD MILLION)
  • TABLE 255. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2018-2024 (USD MILLION)
  • TABLE 256. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY VIRAL, 2025-2030 (USD MILLION)
  • TABLE 257. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 259. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ARGENTINA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, 2025-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2025-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET SIZE, BY PATHOGEN, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS D